Will embryonic stem cells change health policy?

Journal of Law, Medicine and Ethics

Volumn 38, Issue 2, 2010, Pages 342-351

  Sage, William M ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL PRACTICE; COMMODIFICATION; CONFERENCE PAPER; CONFLICT; CONFLICT OF INTEREST; ECONOMIC DEVELOPMENT; ECONOMICS; EMBRYO RESEARCH; EMBRYONIC STEM CELL; ETHICS; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MASS COMMUNICATION; MASS MEDIUM; ORGANIZATION AND MANAGEMENT; PATIENT ADVOCACY; POLITICS; SAFETY; SOCIAL PSYCHOLOGY; TRANSLATIONAL RESEARCH; UNITED STATES;

COMMODIFICATION; CONFLICT OF INTEREST; DIFFUSION OF INNOVATION; DISSENT AND DISPUTES; ECONOMIC DEVELOPMENT; EMBRYO RESEARCH; EMBRYONIC STEM CELLS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MASS MEDIA; PATIENT ADVOCACY; PHYSICIAN'S PRACTICE PATTERNS; POLITICS; RESEARCH SUPPORT AS TOPIC; SAFETY; SOCIAL VALUES; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 77954921262     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2010.00493.x     Document Type: Conference Paper

References (51)

1. Brock D W. " Creating Embryos for Use in Stem Cell Research," Journal of Law, Medicine & Ethics 2010, 38(no. 2).
2. Green R M. " Political Interventions in U.S. Human Embryo Research: An Ethical Assessment," Journal of Law, Medicine & Ethics 2010, 38(no. 2). See, e.g.
3. Goldstein L. " Why Scientific Details Are Important When Novel Technologies Encounter Law, Politics, and Ethics," Journal of Law, Medicine & Ethics 2010, 38(no. 2). See, e.g.
4. Sage W M. " Malpractice Insurance and the Emperor's Clothes," DePaul Law Review 2005, 54(no. 2):463-484.
5. Marmor T. The Politics of Medicare 2000, 2nd ed., New Brunswick, NJ, AldineTransaction, D. Hyman, (Washington, D.C.: Cato Institute, 2006)
6. " CIRM Creates a Unique Environment for Stem Cell Research in California," http://www.cirm.ca.gov/StemCellBasics_California, California Institute for Regenerative Medicine, , last visited April 20, 2010
7. All 12 CIRM Major Facility Projects Moving Forward, Creating Jobs Today and Hope for Cures Tomorrow. http://www.cirm.ca.gov/PressRelease_011510, California Institute for Regenerative Medicine, Press Release,, last visited April 20, 2010
8. Kahan D M, Braman D, Mandel G N. " Risk and Culture: Is Synthetic Biology Different?" February 2009, http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1347165, last visited April 20, 2010
9. Vladeck B C. " The Political Economy of Medicare," Health Affairs 1999, 18(no. 1):22-36.
10. Executive Order No. 13,505, Federal Register 74 (March 11, 2009): 10,667-10,668.
11. Sage W M. " Fraud and Abuse Law," JAMA 1999, 281(no. 12):1179-1181.
12. Spar D, Harrington A. " Selling Stem Cell Science: How Markets Drive the Law along the Technological Frontier," American Journal of Law and Medicine 2007, 33(no. 4):541-565.
13. Jensen J, Hyllner J, Bjorquist P. " Human Embryonic Stem Cell Technologies and Drug Discovery," Journal of Cellular Physiology 2009, 219(no. 3):513-519.
14. Kola I, Landis J. " Can the Pharmaceutical Industry Reduce Attrition Rates?" Nature Reviews Drug Discovery 2004, 3(no. 8):711-715.
15. Lazarou J, Pomeranz B H, Corey P N. " Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies," JAMA 1998, 279(no. 15):1200-1205.
16. Prentis R A, Lis Y, Walker S R. " Pharmaceutical Innovation by the Seven UK-Owned Pharmaceutical Companies (1964-1985)," British Journal of Clinical Pharmacology 1988, 25(no. 3):387-396.
17. Améen C, Strehl R, Björquist P, Lindahl A, Hyllner J, Sartipy P. " Human Embryonic Stem Cells: Current Technologies and Emerging Industrial Applications," Critical Reviews in Oncology/Hematology 2008, 65(no. 1):54-80.
18. Clarke S E, Jeffrey P. " Utility of Metabolic Stability Screening: Comparison of In Vitro and In Vivo Clearance," Xenobiotica 2001, 31(nos. 8-9):591-598.
19. Shah R R. " The Significance of QT Interval in Drug Development," British Journal of Clinical Pharmacology 2002, 54(no. 2):188-202.
20. Meinardi M T, Gietema J A, van Veldhuisen D J, van der Graaf W T, de Vries E G, Sleijfer D T. " Long-Term Chemotherapy-Related Cardiovascular Morbidity," Cancer Treatment Reviews 2000, 26(no. 6):429-447.
21. Schwartz R E, Linehan J L, Painschab M S, Hu W S, Verfaillie C M, Kaufman D S. " Defined Conditions for Development of Functional Hepatic Cells from Human Embryonic Stem Cells," Stem Cells and Development 2005, 14(no. 6):643-655.
22. Dolnikov K, Shilkrut M, Zeevi-Levin N. " Functional Properties of Human Embryonic Stem Cell-Derived Cardiomyocytes," Annals of New York Academy of Sciences June 2005, 1047:66-75.
23. Kehat I, Kenyagin-Karsenti D, Snir M. " Human Embryonic Stem Cells Can Differentiate into Myocytes with Structural and Functional Properties of Cardiomyocytes," Journal of Clinical Investigation 2001, 108(no. 3):407-414.
24. Takahashi K, Yamanaka S. " Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors," Cell 2006, 126(no. 4):663-676. The original iPSC experiment reprogrammed adult skin cells to a pluripotent state similar to that of hESCs
25. Dimos J, Rodolfa K T, Niakan K K. " Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons," Science 2008, 321(no. 5893):1218-1221.
26. Golden J M. " WARF's Stem Cell Patents and Tensions between Public and Private Sector Approaches to Research," Journal of Law, Medicine & Ethics 2010, 38(no. 2).
27. Sage W M. " Some Principles Require Principals: Why Banning 'Conflicts of Interest' Won't Solve Incentive Problems in Biomedical Research," Texas Law Review 2007, 85(no. 6):1413-1463.
28. Berg P. " Asilomar 1975: DNA Modification Secured," Nature 2008, 455(no. 7211):290-291.
29. Thomas L. The Lives of a Cell: Notes of a Biology Watcher 1978, New York, Penguin, at 5-42
30. Shapiro A M, Lakey J, Ryan E, Korbutt G, Toth E, Warnock G, Kneteman N, Rajotte R. " Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using Glucocorticoid-Free Immunosuppressive Regimen," New England Journal of Medicine 2000, 343(no. 4):230-238.
31. Shapiro A M, Ricordi C, Hering B J, Auchincloss H, Lindblad R, Robertson R P, Secchi A, Brendel M D, Berney T, Brennan D C. " International Trial of the Edmonton Protocol for Islet Transplantation," New England Journal of Medicine 2006, 355(no. 13):1318-1330.
32. Soria B, Roche E, Berna G, Leon-Quinto T, Reig J A, Martin F. " Insulin-Secreting Cells Derived from Embryonic Stem Cells Normalize Glycemia in Streptozotocin-Induced Diabetic Mice," Diabetes 2000, 49(no. 2):157-162.
33. Soria B. " In-Vitro Differentiation of Pancreatic Beta-Cells," Differentiation 2001, 68(nos. 4-5):205-219.
34. Segev H, Fishman B, Ziskind A, Shulman M, Itskovitz-Eldor J. " Differentiation of Human Embryonic Stem Cells into Insulin-Producing Clusters," Stem Cells 2004, 22(no. 3):265-274.
35. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton D. " In Vivo Reprogramming of Adult Pancreatic Exocrine Cells to β-Cells," Nature 2008, 455(no. 7213):627-632.
36. " Prevalence of Age-Related Macular Degeneration in the United States," http://www.nei.nih.gov/eyedata/pbd4.asp, National Eye Institute, , last visited April 21, 2010
37. A recent study supported the safety and effectiveness of implanting hESC-RPE cells into the sub-retinal space of rats. The study demonstrated the ability of hESC-RPE cells to survive after transplantation for more than 8 months and showed a dose-dependent improvement in visual acuity and luminance threshold response. Just as importantly, there was no evidence of pathological consequences or teratoma formation, clearing the way for potential Phase I clinical trials. B. Lu, C. Malcuit, and S. Wang et al., " Long-Term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration," 27, no. 9 (2009): 2126-2135.
38. Kaplan K. " Company Seeks FDA Permission to Conduct Clinical Trial Using Human Embryonic Stem Cells," http://latimesblogs.latimes.com/booster_shots/2009/11/human-embyronic-stem-cells-stargardts-macular-dystrophy.html, last visited April 21, 2010
39. Geron. Geron Comments on FDA Hold on Spinal Cord Injury Trial: Press Release. http://www.geron.com/media/pressview.aspx?id=1188, last visited April 21, 2010
40. Keirstead H, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp S, Steward O. " Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Transplants Remyelinate and Restore Locomotion After Spinal Cord Injury," Journal of Neuroscience 2005, 25(no. 19):4694-4705.
41. Dresser R. " Stem Cell Research as Innovation: Expanding the Ethical and Policy Conversation," Journal of Law, Medicine & Ethics 2010, 38(no. 2).
42. Gersh B J, Simari R D, Behfar A, Terzic C M, Terzic A. " Cardiac Cell Repair Therapy: A Clinical Perspective," Mayo Clinic Proceedings October 2009, 84(no. 10):876-892.
43. available at. http://www.unos.org, United Network for Organ Sharing, last visited April 21, 2010
44. " Transplant Programs at Mayo Clinic," http://www.mayoclinic.org/transplant/organ-donation.html, Mayo Clinic, , last visited April 21, 2010
45. Zhu W Z, Hauch K D, Xu C, Laflamme M A. " Human Embryonic Stem Cells and Cardiac Repair," Transplatation Reviews January 2009, 23(no. 1):53-68.
46. New procedures to induce cardiogenesis and enrich cardiomyocite cultures have resulted in hESC-CM preparations with greater than 93% purity and greater than 85% viability, greatly reducing safety and scalability concerns
47. Laflamme M A, Chen K Y, Naumova A V. " Cardiomyocytes Derived from Human Embryonic Stem Cells in Pro-survival Factors Enhance Function of Infarcted Rat Hearts," Nature Biotechnology 2007, 25(no. 9):1015-1024.
48. Abdel-Latif A, Bolli R, Tleyjeh I M. " Adult Bone Marrow-Derived Cells for Cardiac Repair: A Systematic Review and Meta-Analysis," Archives of Internal Medicine 2007, 167(no. 10):989-997. M. Hristov, N. Heussen, A. Schober, and C. Weber, " Intracoronary Infusion of Autologous Bone Marrow Cells and Left Ventricular Function After Acute Myocardial Infarction: A Meta-analysis," 10, no. 3 (2006): 727-733; M. J. Lipinski, G. G. Biondi-Zoccai, and A. Abbate et al., " Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction: A Collaborative Systematic Review and Meta-analysis of Controlled Clinical Trials," 50, no. 18 (October 30, 2007): 1761-1767; E. Martin-Rendon, S. J. Brunskill, C. J. Hyde, S. J. Stanworth, A. Mathur, and S. M. Watt, " Autologous Bone Marrow Stem Cells to Treat Acute Myocardial Infarction: A Systematic Review," 29, no. 15 (August 2008): 1807-1818.
49. See Gersh et al., note 42.
50. Richardson L S. " Criminal Law: When Human Experimentation Is Criminal," Journal of Criminal Law and Criminology 2009, 99(no. 2):89-133.
51. Jacobs L R. " The Politics of America's Supply State: Health Reform and Medical Technology," Health Affairs 1995, 14(no. 2):143-157. W. M. Sage, " Relational Duties, Regulatory Duties, and the Widening Gap between Individual Health Law and Collective Health Policy," 96, no. 2 (2008): 497-522.